These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 25650893)
1. Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma. Ben-Shabat I; Hansson C; Sternby Eilard M; Cahlin C; Rizell M; Lindnér P; Mattsson J; Olofsson Bagge R J Vis Exp; 2015 Jan; (95):52490. PubMed ID: 25650893 [TBL] [Abstract][Full Text] [Related]
2. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Noter SL; Rothbarth J; Pijl ME; Keunen JE; Hartgrink HH; Tijl FG; Kuppen PJ; van de Velde CJ; Tollenaar RA Melanoma Res; 2004 Feb; 14(1):67-72. PubMed ID: 15091197 [TBL] [Abstract][Full Text] [Related]
3. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases. Carr MJ; Sun J; Cohen JB; Liu J; Serdiuk AA; Stewart SR; Doobay N; Duclos A; Seal DA; Choi J; Zager JS Cancer Control; 2020; 27(1):1073274820983019. PubMed ID: 33372814 [TBL] [Abstract][Full Text] [Related]
4. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785 [TBL] [Abstract][Full Text] [Related]
5. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. van Iersel LB; de Leede EM; Vahrmeijer AL; Tijl FG; den Hartigh J; Kuppen PJ; Hartgrink HH; Gelderblom H; Nortier JW; Tollenaar RA; van de Velde CJ Eur J Surg Oncol; 2014 Nov; 40(11):1557-63. PubMed ID: 25125340 [TBL] [Abstract][Full Text] [Related]
6. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study. Vogl TJ; Koch SA; Lotz G; Gebauer B; Willinek W; Engelke C; Brüning R; Zeile M; Wacker F; Vogel A; Radeleff B; Scholtz JE Cardiovasc Intervent Radiol; 2017 Jun; 40(6):864-872. PubMed ID: 28144756 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. Ben-Shabat I; Belgrano V; Ny L; Nilsson J; Lindnér P; Olofsson Bagge R Ann Surg Oncol; 2016 Apr; 23(4):1327-34. PubMed ID: 26628434 [TBL] [Abstract][Full Text] [Related]
8. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. Dewald CLA; Becker LS; Maschke SK; Meine TC; Alten TA; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB Clin Exp Metastasis; 2020 Dec; 37(6):683-692. PubMed ID: 33034815 [TBL] [Abstract][Full Text] [Related]
9. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. Karydis I; Gangi A; Wheater MJ; Choi J; Wilson I; Thomas K; Pearce N; Takhar A; Gupta S; Hardman D; Sileno S; Stedman B; Zager JS; Ottensmeier C J Surg Oncol; 2018 May; 117(6):1170-1178. PubMed ID: 29284076 [TBL] [Abstract][Full Text] [Related]
10. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Lindnér P; Fjälling M; Hafström L; Kierulff-Nielsen H; Mattsson J; Scherstén T; Rizell M; Naredi P Eur J Surg Oncol; 1999 Apr; 25(2):179-85. PubMed ID: 10218462 [TBL] [Abstract][Full Text] [Related]
11. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. Verhoef C; de Wilt JH; Brunstein F; Marinelli AW; van Etten B; Vermaas M; Guetens G; de Boeck G; de Bruijn EA; Eggermont AM Ann Surg Oncol; 2008 May; 15(5):1367-74. PubMed ID: 18239976 [TBL] [Abstract][Full Text] [Related]
12. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793 [TBL] [Abstract][Full Text] [Related]
14. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases. De Vries MR; Borel Rinkes IH; Swaak AJ; Hack CE; Van De Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Eggermont AM Eur J Clin Invest; 1999 Jun; 29(6):553-60. PubMed ID: 10354218 [TBL] [Abstract][Full Text] [Related]
15. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. Schönfeld L; Hinrichs JB; Marquardt S; Voigtländer T; Dewald C; Koppert W; Manns MP; Wacker F; Vogel A; Kirstein MM J Cancer Res Clin Oncol; 2020 Nov; 146(11):3003-3012. PubMed ID: 32564137 [TBL] [Abstract][Full Text] [Related]
16. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. van Etten B; de Wilt JH; Brunstein F; Eggermont AM; Verhoef C Eur J Surg Oncol; 2009 May; 35(5):539-45. PubMed ID: 18760560 [TBL] [Abstract][Full Text] [Related]
17. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. van Etten B; Brunstein F; van IJken MG; Marinelli AW; Verhoef C; van der Sijp JR; Guetens G; de Boeck G; de Bruijn EA; de Wilt JH; Eggermont AM Ann Surg Oncol; 2004 Jun; 11(6):598-605. PubMed ID: 15172933 [TBL] [Abstract][Full Text] [Related]
18. Isolated hepatic perfusion for liver metastases of malignant melanoma. Rizell M; Mattson J; Cahlin C; Hafström L; Lindner P; Olausson M Melanoma Res; 2008 Apr; 18(2):120-6. PubMed ID: 18337648 [TBL] [Abstract][Full Text] [Related]
19. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. van Iersel LB; Hoekman EJ; Gelderblom H; Vahrmeijer AL; van Persijn van Meerten EL; Tijl FG; Hartgrink HH; Kuppen PJ; Nortier JW; Tollenaar RA; van de Velde CJ Ann Surg Oncol; 2008 Jul; 15(7):1891-8. PubMed ID: 18470571 [TBL] [Abstract][Full Text] [Related]
20. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. de Vries MR; Borel Rinkes IH; van de Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Vahrmeijer AL; Eggermont AM Recent Results Cancer Res; 1998; 147():107-19. PubMed ID: 9670273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]